Biomea Fusion Receives Buy Rating as Diabetes Drug Shows Sustained Benefits
Rodman & Renshaw initiated coverage of Biomea Fusion with a Buy rating and $8 price target. The company reported durable Phase II data for its diabetes drug icovamenib, showing sustained HbA1c reductions months after treatment ended.